1-18 of 18
Matthew M. Ames
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2

Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, Edward Brent Perkins, Viswanathan Ramakrishnan, Mary Beth Tombes, Connie Honeycutt, Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, Martha D. Wellons, Heidi Sankala, Austin Doyle, John Wright, John D. Roberts, Steven Grant
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1873–1883.
https://doi.org/10.1158/1078-0432.CCR-12-2926
Published: 02 April 2013
View article titled, A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2
Open the PDF for A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 in another window
Includes: Supplementary data
Journal Articles

CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8

Matthew P. Goetz, Vera J. Suman, Tanya L. Hoskin, Michael Gnant, Martin Filipits, Stephanie L. Safgren, Mary Kuffel, Raimund Jakesz, Margaretha Rudas, Richard Greil, Otto Dietze, Alois Lang, Felix Offner, Carol A. Reynolds, Richard M. Weinshilboum, Matthew M. Ames, James N. Ingle
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (2): 500–507.
https://doi.org/10.1158/1078-0432.CCR-12-2153
Published: 16 January 2013
View article titled, CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8
Open the PDF for CYP2D6 Metabolism and Patient Outcome in the Austrian Breast and Colorectal Cancer Study Group Trial (ABCSG) 8 in another window
Journal Articles

Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03

Eudocia Q. Lee, Vinay K. Puduvalli, Joel M. Reid, John G. Kuhn, Kathleen R. Lamborn, Timothy F. Cloughesy, Susan M. Chang, Jan Drappatz, W. K. Alfred Yung, Mark R. Gilbert, H. Ian Robins, Frank S. Lieberman, Andrew B. Lassman, Renee M. McGovern, Jihong Xu, Serena Desideri, Xiabu Ye, Matthew M. Ames, Igor Espinoza-Delgado, Michael D. Prados, Patrick Y. Wen
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (21): 6032–6039.
https://doi.org/10.1158/1078-0432.CCR-12-1841
Published: 06 November 2012
View article titled, Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03
Open the PDF for Phase I Study of Vorinostat in Combination with Temozolomide in Patients with High-Grade Gliomas: North American Brain Tumor Consortium Study 04-03 in another window
Includes: Supplementary data
Journal Articles

Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group

Judith G. Villablanca, Wendy B. London, Arlene Naranjo, Patrick McGrady, Matthew M. Ames, Joel M. Reid, Renee M. McGovern, Sarah A. Buhrow, Hollie Jackson, Enno Stranzinger, Brenda J. Kitchen, Paul M. Sondel, Marguerite T. Parisi, Barry Shulkin, Gregory A. Yanik, Susan L. Cohn, C. Patrick Reynolds
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6858–6866.
https://doi.org/10.1158/1078-0432.CCR-11-0995
Published: 31 October 2011
View article titled, Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group
Open the PDF for Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group in another window
Journal Articles

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials

Matthew P. Goetz, Daniel J. Schaid, D. Lawrence Wickerham, Stephanie Safgren, Taisei Mushiroda, Michiaki Kubo, Anthony Batzler, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura, Richard M. Weinshilboum, James N. Ingle, Matthew M. Ames
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6944–6951.
https://doi.org/10.1158/1078-0432.CCR-11-0860
Published: 31 October 2011
View article titled, Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
Open the PDF for Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance

Matthew P. Goetz, Vera J. Suman, Fergus J. Couch, Matthew M. Ames, James M. Rae, Mark G. Erlander, Xiao-Jun Ma, Dennis C. Sgroi, Carol A. Reynolds, Wilma L. Lingle, Richard M. Weinshilboum, David A. Flockhart, Zeruesenay Desta, Edith A. Perez, James N. Ingle
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (18): 5864–5868.
https://doi.org/10.1158/1078-0432.CCR-08-0619
Published: 14 September 2008
View article titled, Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance
Open the PDF for Cytochrome P450 2D6 and Homeobox 13/Interleukin-17B Receptor: Combining Inherited and Tumor Gene Markers for Prediction of Tamoxifen Resistance in another window
Journal Articles

A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer

Grzegorz S. Nowakowski, Andrea K. McCollum, Matthew M. Ames, Sumithra J. Mandrekar, Joel M. Reid, Alex A. Adjei, David O. Toft, Stephanie L. Safgren, Charles Erlichman
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (20): 6087–6093.
https://doi.org/10.1158/1078-0432.CCR-06-1015
Published: 24 October 2006
View article titled, A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer
Open the PDF for A Phase I Trial of Twice-Weekly 17-Allylamino-Demethoxy-Geldanamycin in Patients with Advanced Cancer in another window
Journal Articles

Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics

Judith A. Gilbert, Oreste E. Salavaggione, Yuan Ji, Linda L. Pelleymounter, Bruce W. Eckloff, Eric D. Wieben, Matthew M. Ames, Richard M. Weinshilboum
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (6): 1794–1803.
https://doi.org/10.1158/1078-0432.CCR-05-1969
Published: 21 March 2006
View article titled, Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics
Open the PDF for Gemcitabine Pharmacogenomics: Cytidine Deaminase and Deoxycytidylate Deaminase Gene Resequencing and Functional Genomics in another window
Includes: Supplementary data
Journal Articles

Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia

Scott H. Kaufmann, Judith E. Karp, Louis Letendre, Timothy J. Kottke, Stephanie Safgren, Jackie Greer, Ivana Gojo, Pamela Atherton, Phyllis A. Svingen, David A. Loegering, Mark R. Litzow, Jeff A. Sloan, Joel M. Reid, Matthew M. Ames, Alex A. Adjei, Charles Erlichman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (18): 6641–6649.
https://doi.org/10.1158/1078-0432.CCR-05-0817
Published: 15 September 2005
View article titled, Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia
Open the PDF for Phase I and Pharmacologic Study of Infusional Topotecan and Carboplatin in Relapsed and Refractory Acute Leukemia in another window
Journal Articles

Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points

Keith C. Bible, Janet L. Lensing, Sacha A. Nelson, Yean K. Lee, Joel M. Reid, Matthew M. Ames, Crescent R. Isham, Jill Piens, Stacie L. Rubin, Joseph Rubin, Scott H. Kaufmann, Pamela J. Atherton, Jeffrey A. Sloan, Michelle K. Daiss, Alex A. Adjei, Charles Erlichman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (16): 5935–5941.
https://doi.org/10.1158/1078-0432.CCR-04-2566
Published: 22 August 2005
View article titled, Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points
Open the PDF for Phase 1 Trial of Flavopiridol Combined with Cisplatin or Carboplatin in Patients with Advanced Malignancies with the Assessment of Pharmacokinetic and Pharmacodynamic End Points in another window
Journal Articles

The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes

Joel M. Reid, Denise L. Walker, Jennifer K. Miller, Linda M. Benson, Andrew J. Tomlinson, Stephen Naylor, April L. Blajeski, Patricia M. LoRusso, Matthew M. Ames
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (4): 1471–1480.
https://doi.org/10.1158/1078-0432.CCR-0557-03
Published: 20 February 2004
View article titled, The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes
Open the PDF for The Metabolism of Pyrazoloacridine (NSC 366140) by Cytochromes P450 and Flavin Monooxygenase in Human Liver Microsomes in another window
Journal Articles

Rat and Human Liver Cytochrome P-450 Isoform Metabolism of Ecteinascidin 743 Does Not Predict Gender-dependent Toxicity in Humans

Joel M. Reid, Mary J. Kuffel, Stacie L. Ruben, Jose J. Morales, Kenneth L. Rinehart, David P. Squillace, Matthew M. Ames
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (9): 2952–2962.
Published: 01 September 2002
View article titled, Rat and Human Liver Cytochrome P-450 Isoform Metabolism of Ecteinascidin 743 Does Not Predict Gender-dependent Toxicity in Humans
Open the PDF for Rat and Human Liver Cytochrome P-450 Isoform Metabolism of Ecteinascidin 743 Does Not Predict Gender-dependent Toxicity in Humans in another window
Journal Articles

A Phase I Study of Bizelesin (NSC 615291) in Patients with Advanced Solid Tumors

Henry C. Pitot, Joel M. Reid, Jeff A. Sloan, Matthew M. Ames, Alex A. Adjei, Joseph Rubin, Pamela G. Bagniewski, Pamela Atherton, Daniel Rayson, Richard M. Goldberg, Charles Erlichman
Journal: Clinical Cancer Research
Clin Cancer Res (2002) 8 (3): 712–717.
Published: 01 March 2002
View article titled, A Phase I Study of Bizelesin (NSC 615291) in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of Bizelesin (NSC 615291) in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities

Francisco Bracho, Mark D. Krailo, Violet Shen, Sharon Bergeron, Virginia Davenport, Wen Liu-Mares, Bruce R. Blazar, Angela Panoskaltsis-Mortari, Carmella van de Ven, Rita Secola, Matthew M. Ames, Joel M. Reid, Gregory H. Reaman, Mitchell S. Cairo
Journal: Clinical Cancer Research
Clin Cancer Res (2001) 7 (1): 58–67.
Published: 01 January 2001
View article titled, A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities
Open the PDF for A Phase I Clinical, Pharmacological, and Biological Trial of Interleukin 6 Plus Granulocyte-Colony Stimulating Factor after Ifosfamide, Carboplatin, and Etoposide in Children with Recurrent/Refractory Solid Tumors: Enhanced Hematological Responses but a High Incidence of Grade III/IV Constitutional Toxicities in another window
Journal Articles

The Aromatic-l-Amino Acid Decarboxylase Inhibitor Carbidopa Is Selectively Cytotoxic to Human Pulmonary Carcinoid and Small Cell Lung Carcinoma Cells1

Judith A. Gilbert, Linda M. Frederick, Matthew M. Ames
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (11): 4365–4372.
Published: 01 November 2000
View article titled, The Aromatic-<sc>l</sc>-Amino Acid Decarboxylase Inhibitor Carbidopa Is Selectively Cytotoxic to Human Pulmonary Carcinoid and Small Cell Lung Carcinoma Cells1
Open the PDF for The Aromatic-<sc>l</sc>-Amino Acid Decarboxylase Inhibitor Carbidopa Is Selectively Cytotoxic to Human Pulmonary Carcinoid and Small Cell Lung Carcinoma Cells1 in another window
Journal Articles

Phase I Study of Topotecan Administered as a 21-Day Continuous Infusion in Children with Recurrent Solid Tumors: A Report from the Children’s Cancer Group

Haydar Frangoul, Matthew M. Ames, Revonda B. Mosher, Joel M. Reid, Mark D. Krailo, Nita L. Seibel, Dennis W. W. Shaw, Peter G. Steinherz, James A. Whitlock, John S. Holcenberg
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (12): 3956–3962.
Published: 01 December 1999
View article titled, Phase I Study of Topotecan Administered as a 21-Day Continuous Infusion in Children with Recurrent Solid Tumors: A Report from the Children’s Cancer Group
Open the PDF for Phase I Study of Topotecan Administered as a 21-Day Continuous Infusion in Children with Recurrent Solid Tumors: A Report from the Children’s Cancer Group in another window
Journal Articles

Metabolic Activation of Dacarbazine by Human Cytochromes P450: The Role of CYP1A1, CYP1A2, and CYP2E1

Joel M. Reid, Mary J. Kuffel, Jennifer K. Miller, Robert Rios, Matthew M. Ames
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (8): 2192–2197.
Published: 01 August 1999
View article titled, Metabolic Activation of Dacarbazine by Human Cytochromes P450: The Role of CYP1A1, CYP1A2, and CYP2E1
Open the PDF for Metabolic Activation of Dacarbazine by Human Cytochromes P450: The Role of CYP1A1, CYP1A2, and CYP2E1 in another window
Journal Articles

Phase I Trial of Dolastatin-10 (NSC 376128) in Patients with Advanced Solid Tumors

Henry C. Pitot, Edwin A. McElroy, Jr., Joel M. Reid, Anthony J. Windebank, Jeff A. Sloan, Charles Erlichman, Pamela G. Bagniewski, Denise L. Walker, Joseph Rubin, Richard M. Goldberg, Alex A. Adjei, Matthew M. Ames
Journal: Clinical Cancer Research
Clin Cancer Res (1999) 5 (3): 525–531.
Published: 01 March 1999
View article titled, Phase I Trial of Dolastatin-10 (NSC 376128) in Patients with Advanced Solid Tumors
Open the PDF for Phase I Trial of Dolastatin-10 (NSC 376128) in Patients with Advanced Solid Tumors in another window